# Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer

> **NCT03428126** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 29 (actual)

## Conditions studied

- Malignant Neoplasms of Digestive Organs
- Colorectal Cancer
- Colon Cancer

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Trametinib

## Key facts

- **NCT ID:** NCT03428126
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-21
- **Primary completion:** 2022-05-05
- **Final completion:** 2022-05-05
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2023-06-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03428126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03428126, "Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT03428126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*